Congresswoman Nikema Williams Signs Amicus Brief Urging Appeals Court to Prevent Dangerous Ruling Threatening Access to Mifepristone From Taking Effect

Apr 12, 2023
Press

WASHINGTON On Tuesday, Congresswoman Nikema Williams (GA-05) joined 189 members of the House of Representatives and 50 Senators in submitting an amicus brief to the U.S. Court of Appeals for the Fifth Circuit in the case of Alliance for Hippocratic Medicine v. FDA, in support of the Biden administration’s appeal of federal district court judge Matthew J. Kacsmaryk’s Friday ruling that suspends the Food and Drug Administration’s (FDA) more than 20-year-old approval of mifepristone—threatening access to mifepristone for patients nationwide, as well as FDA’s Congressionally-mandated authority and drug approval process.

In the new amicus brief, the Members of Congress underscore that the district court ruling has no basis in law, risks denying patients in every part of the country access to mifepristone, a safe and effective medication widely used in abortion care and miscarriage management for years, and jeopardizes patients’ access to a wide array of other medications by threatening FDA’s drug approval process, which was designed and mandated by Congress. Accordingly, they ask the court to stay the district court’s order. 

The lawmakers wrote in their brief

“The district court appears to have second-guessed FDA’s scientific determinations with cherry-picked anecdotes and studies, and on that basis, imposed a remedy that could significantly upend the status quo.”

If the district court ruling were left to stand and were to go into effect, the Members stress that not only could patients in every state be denied access to the most common form of abortion care—and a key drug used in miscarriage management—but FDA’s authority to determine the safety and efficacy of other drugs would be put at risk, threatening patients’ access to all manner of other medications. 

The lawmakers continue:

“[T]he district court’s misguided stay under Section 705 of the Administrative Procedure Act will reduce access to abortion, exacerbating an already significant reproductive health crisis. The consequences of the district court’s remedy could extend far beyond mifepristone, for it undermines the science-based, expert-driven process that Congress designed for determining whether drugs are safe and effective…

“Its perilous consequences reach far beyond mifepristone. Providers and patients rely on the availability of thousands of FDA-approved drugs to treat or manage a range of medical conditions, including asthma, HIV, infertility, heart disease, diabetes, and more.”

The Members also explain that Congress specifically designed FDA’s expert-driven drug approval process to ensure that the medications relied on by Americans every day are safe and effective. FDA followed that careful review process before it approved mifepristone for use in 2000, and its approval has been repeatedly affirmed in the more than 20 years since. 

“For the last century, a statutory scheme designed by Congress has assured the safety and effectiveness of the drugs available in the United States. At its core resides the application of scientific standards by agency experts. Here, FDA’s determination that mifepristone is safe and effective is based on a thorough and comprehensive review process prescribed and overseen by the legislative branch.  Since mifepristone’s initial approval in 2000, FDA has repeatedly and consistently reaffirmed that the medication is safe and effective for its approved conditions of use. FDA’s process and conclusions have been validated by both Congress and the Government Accountability Office—and by the lived experience of over 5 million patients who have used the drug in the United States…

“[E]mergency relief from the order is necessary to mitigate the imminent harm facing members of the public, many of whom rely on the availability of mifepristone for reproductive care—and many more rely on the integrity of FDA’s drug approval process for continued access to life-improving and life-saving drugs.  Congress intended to—and did—vest authority in FDA to evaluate and ensure the safety and efficacy of drugs in the United States, and Amici call on this Court to give due weight to that intent.”

Click here to read the amicus brief. 

CONTACT: PressGA05@mail.house.gov 

Congresswoman Nikema Williams proudly serves Georgia’s Fifth Congressional District on the exclusive Financial Services Committee. She is a champion of voting rights and builds on the Fifth District’s legacy as the cradle of the civil rights movement as co-Chair of the Congressional Voting Rights Caucus. Congresswoman Williams is committed to closing the racial wealth gap and ensuring the promise of America for all–regardless of your ZIP code or bank account.

###

Recent Posts


Feb 21, 2024
Press

Congresswoman Nikema Williams Partners with Spelman College to Deliver $14 Million Grant for Atlanta University Center to Increase Research Capabilities

(ATLANTA) – Today, Congresswoman Nikema Williams (GA-05), a member of the Congressional Bipartisan HBCU Caucus announced she helped secure a $14 million grant for Spelman College, in collaboration with Morehouse College, the Morehouse School of Medicine, and Clark Atlanta University. The grant was awarded by the U.S. National Science Foundation (NSF) as part of its […]



Feb 20, 2024
Press

Congresswoman Nikema Williams Reintroduces Legislation to Give Communities More Control to Address Highway Noise

(WASHINGTON) – Today, Congresswoman Nikema Williams (GA-05) reintroduced the Negating Neighborhood Noise Act, legislation to give communities the ability to build noise barriers along existing federal interstate highways. Currently, federal funds cannot be used for noise barriers.  The Negating Neighborhood Noise Act allows Highway Trust Fund dollars to be used to build noise barriers in residential […]



Feb 7, 2024
Press

Congresswoman Nikema Williams Receives A Rating on ECU // LAV Action Fund Scorecard

(WASHINGTON) – Today, Congresswoman Nikema (GA-05) announced she received an A Rating in End Citizens United // Let America Vote Action Fund (ECU // LAV) Legislative Scorecard for the 118th Congress. The scorecard grades members of Congress on their support for important anti-corruption and voting rights measures that Congress has introduced and considered over the […]